Cite

    Wanquet, A. et al. (n.d.). The efficacy and safety of a new reduced-toxicity conditioning with 4 days of once-daily 100 mg/m2 intravenous busulfan associated with fludarabine and antithymocyte globulins prior to allogeneic stem cell transplantation in patients with high-risk myelodysplastic syndrome or acute leukemia. Leukemia & lymphoma. 57 (10), pp. 2315-2320. [Online].